Back

OSE Immunotherapeutics reports €11.1 million cash, runway through December 2026

Verifying
  • OSE Immunotherapeutics reported its cash position and provided an updated clinical and financing outlook.
  • €11.1 million remained on June 30, 2026, supporting operations through December 2026 under current plans.
  • ARTEMIA enrolment remains on schedule for December 2026, while futility analysis shifted to early 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.